Tracy Finken, Shareholder at Philadelphia personal injury law firm Anapol Weiss, has been appointed by the Honorable Robin Rosenberg of the United States District Court, Southern District of Florida as one of the Lead Counsel for the Zantac Multi-District Litigation (MDL).
Tracy completed a rigorous interview process in order to be selected for the steering committee, amongst over sixty applicants. As one of the lead counsel, Tracy will join other expert attorneys from around the country who will spearhead the MDL’s leadership and consolidate efforts as Zantac mass tort cases are litigated.
In addition, the Judge presiding over this litigation has created a unique structure with a Leadership Development Committee for newer MDL lawyers to have an opportunity to be a part of the Plaintiffs’ Steering Committee and to be mentored by more experienced MDL lawyers.
“It is truly an honor to be selected to serve in this leadership role among several of my peers,” Tracy said of the opportunity. “I am also excited to see that women comprise over 50% of the Plaintiffs’ Steering Committee and that there are new opportunities being offered to mentor and add diversity within multi-district litigation.”
Multi-District Litigation (MDLs) are when individual lawsuits for a common product, in the case of a mass tort, are consolidated in order to litigate the lawsuits in a federal court.
The litigation against Zantac contends that the popular heartburn medication (also known by the generic name ranitidine) contains unacceptable levels of a contaminant known as N-Nitrosodimethylamine (NDMA), a probable carcinogen believed to have caused cancers in a number of patients. The lawsuits (case number: 9:20-md-02924-RLR) seek just compensation for their injuries.
Tracy Finken has been a Partner with Anapol Weiss for over twenty years. She is a national expert on pharmaceutical liability and focuses her practice on securing justice for clients in mass torts and class actions. Tracy has served in many leadership roles, including on the Plaintiff’s Executive Committee for the MDL for Proton Pump Inhibitors litigation. Tracy has also been interviewed by print and TV media for commentary in pharmaceutical liability issues.
